NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis
NRX-101 has demonstrated potent activity against resistant urinary pathogens upon FDA review
QIDP designation grants Priority Review and an additional 5 years of additional product exclusivity
3 million Americans develop complicated Urinary...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Grants | Infectious Diseases | Pharmaceuticals | Pyelonephritis | Urinary Tract Infections